Left: before statin treatment; right: same patient, one year after statin treatment. Photo: Harvard University
RPB-supported researchers at Massachusetts Eye and Ear/Harvard Medical School and scientists at University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering medications) for the treatment of patients with the dry form of age-related macular degeneration (AMD) — the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.
The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.
February 5, 2016
This new media campaign shines a spotlight on the powerful benefits of vision research.
David Williams, PhD, is recognized for ground-breaking contributions to the field of vision research.
Dr. Chiang is a respected scientist, clinician and leader in vision research.
RPB is increasing both the amount of funding and the number of awards funded through its flagship grant in order to better support early-career vision scientists.
The organizations announce new grants to increase funding for innovative research from early-career vision scientists.
For the past 60 years, RPB has funded groundbreaking research to prevent, treat and cure all conditions that damage or destroy sight.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |